Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy

Richard David Semba, Nina Shah, David Vlahov

Research output: Contribution to journalArticle

Abstract

Although anemia is common during HIV infection, it is unclear whether potent antiretroviral therapy would improve or worsen anemia. We conducted a study to examine the impact of highly active antiretroviral therapy (HAART) on anemia in a cohort of HIV-positive injection drug users (IDUs) in Baltimore, Maryland. At baseline, the overall prevalence of anemia was 40%. During mean follow-up of one year, among 102 subjects who received HAART, there was a mean increase in hemoglobin of 3.6 ± 1.7 g/L (p = .04) and a mean decrease in log10 plasma HIV load of 0.78 ± 0.17 copies/ml (p 10 plasma HIV load of 0.25 ± 0.06 copies/ml (p

Original languageEnglish (US)
Pages (from-to)315-319
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume26
Issue number4
Publication statusPublished - Apr 1 2001
Externally publishedYes

    Fingerprint

Keywords

  • AIDS
  • Anemia
  • Chronic disease
  • Hemoglobin
  • HIV
  • Protease inhibitors

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this